It said the US regulator had granted a priority review for its new cancer treatment and told investors a phase III trial of its diabetes medication delivered impressive results.
AZ said Lynparza, which it jointly developed with Merck, is being put forward as a front-line treatment for BRCA-mutated ovarian cancer.
If approved it would be the fourth indication for the tablet, which is a new form of cancer combatant called a PARP inhibitor.
Meanwhile, a final-phase clinical study showed its drug candidate Farxiga significantly reduced hospitalisation for heart failure and incidents of cardiovascular death in people assessed who had type-2 diabetes.
“These positive results are clinically relevant to the 425mln people worldwide living with diabetes, of whom those with type-2 diabetes have two-to-five times greater risk of heart failure along with an increased risk of a heart attack or stroke,” said Elisabeth Bjork, AZ’s head of cardiovascular.